BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GS 9256: Additional Phase IIa data

Additional data from the open-label, international Phase IIa Study 196-0112 trial in 42 treatment-naïve patients with HCV genotype 1 infection showed that dual therapy with twice-daily 40 mg tegobuvir and twice-daily 75 mg GS 9256 (n=15) produced an RVR rate defined as HCV RNA levels <=25 IU/mL at day 28 of 7%. Triple therapy with tegobuvir,...

Read the full 268 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >